Proteomics

Dataset Information

0

NEOPALANA Proteomgenomic analysis

ABSTRACT: Neoadjuvant palbociclib and anastrozole (NeoPalAna) is a single-arm phase II clinical trial for patients with stage II/III ER+/HER2- breast cancer. Patients recieved Anastrozole for 4weeks followed by palbociclib. On day 15, patients were biopsied and Ki67% was determined. Patients with Ki67 >10% were deemed resistant to therapy. These biopsies were subsequently frozen for multi-omics processing

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Breast Cancer Cell

DISEASE(S): Breast Cancer

SUBMITTER: Matthew Holt  

LAB HEAD: Matthew V Holt

PROVIDER: PXD058250 | Pride | 2026-02-09

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
NeoPalAna_1525228_ME480_EV1106_500ng_FAIMS_-45CV_DIA_44min_1_1.raw Raw
NeoPalAna_1537978_ME480_EV1106_500ng_FAIMS_-45CV_DIA_44min_1_1.raw Raw
NeoPalAna_1550455_ME480_EV1106_500ng_FAIMS_-45CV_DIA_44min_1_1.raw Raw
NeoPalAna_1563376_ME480_EV1106_500ng_FAIMS_-45CV_DIA_44min_1_1.raw Raw
NeoPalAna_1564140_ME480_EV1106_500ng_FAIMS_-45CV_DIA_44min_1_1.raw Raw
Items per page:
1 - 5 of 21
altmetric image

Publications

Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.

Kong Tim T   Mabry Alex A   Highkin Maureen M   Wang Anthony Z AZ   Hoog Jeremy J   Guo Zhanfang Z   Gonzales-Gonzales Adrian A   Thomas Shana S   Song Yingduo Y   Gao Feng F   Opyrchal Mateusz M   Peterson Lindsay L   Ademuyiwa Foluso F   Margenthaler Julie J   Aft Rebecca R   Glover-Collins Katherine K   Nehring Leslie L   Tao Yu Y   Sanati Souzan S   Hagemann Ian S IS   Boulos Fouad F   Holt Matthew M   Ding Li L   Zhu Wenge W   Oh Stephen T ST   Wang Jianxin J   Witkiewicz Agnieszka K AK   Knudsen Erik S ES   Bose Ron R   Weber Jason D JD   Goetz Matthew M   Northfelt Donald D   Luo Jingqin J   Ma Cynthia X CX  

Nature communications 20260127 1

CDK4/6 inhibitors (CDK4/6i) improve outcomes for estrogen receptor (ER) positive/HER2-negative breast cancers (BCs), yet intrinsic and acquired resistance exist. Here, we evaluated anastrozole in combination with palbociclib (ANA/PAL) in the NeoPalAna Endocrine-Resistant cohort (NCT01723774). Thirty-four patients with clinical stage II/III ER + /HER2- BCs resistant to standard neoadjuvant endocrine therapy (on-treatment Ki67 > 10%) received neoadjuvant ANA/PAL, with serial biopsies analyzed. The  ...[more]

Similar Datasets

Transcriptomics A Phase II Randomized Trial of Neoadjuvant Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Docetaxel and Carboplatin with Trastuzumab and/or Lapatinib in Patients with HER2+ Breast Cancer [treatments]
2019-05-08 | GSE130787 | GEO
Transcriptomics A Phase II Randomized Trial of Neoadjuvant Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Docetaxel and Carboplatin with Trastuzumab and/or Lapatinib in Patients with HER2+ Breast Cancer [Baseline]
2019-05-08 | GSE130786 | GEO
Transcriptomics Assessment of tumor pathological and transcriptional biomarkers in pre- and on-treatment core biopsies predictive of response and outcome after neoadjuvant chemotherapy plus Bevacizumab in patients with HER2-negative breast cancer
2017-09-01 | GSE87455 | GEO
Transcriptomics On-treatment transcriptional profiling in HER2+ inflammatory breast cancer
2022-09-01 | GSE207248 | GEO
Transcriptomics Gene expression profiling of primary HER2-positive breast cancers treated with neoadjuvant trastuzumab
2016-03-31 | E-GEOD-62327 | biostudies-arrayexpress
Transcriptomics HER2-enriched tumor initiating cell (HTIC) genomic predictor of response following neoadjuvant trastuzumab-based chemotherapy in HER2+ breast cancer
2012-05-11 | E-GEOD-37946 | biostudies-arrayexpress
Transcriptomics Transcriptomic analysis of the NA-PHER2 clinical trial
2024-10-31 | E-MTAB-14448 | biostudies-arrayexpress
Proteomics Human breast cancer biopsies of patients treated or not with the combination of palbociclib and fulvestrant
2025-05-07 | PXD053296 | Pride
Transcriptomics Characterizing of Breast Cancer translational PEARL clinical trial
2023-01-26 | GSE223700 | GEO
Genomics Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast cancer [copy number]
2015-10-06 | GSE66398 | GEO